Clinical Trials Browser

OTHER × Carcinoma in Situ × Biopsy × Clear all

NCT02901548 2022-07-29

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Phase 2 Terminated

17 enrolled 9 charts

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ